In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters

MLA

Inken Salewski, et al. “In Vivo Vaccination with Cell Line-Derived Whole Tumor Lysates: Neoantigen Quality, Not Quantity Matters.” Journal of Translational Medicine, vol. 18, no. 1, Oct. 2020, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12967-020-02570-y.

APA

Inken Salewski, Yvonne Saara Gladbach, Steffen Kuntoff, Nina Irmscher, Olga Hahn, Christian Junghanss, & Claudia Maletzki. (2020). In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters. Journal of Translational Medicine, 18(1), 1–15. https://doi.org/10.1186/s12967-020-02570-y

Chicago

Inken Salewski, Yvonne Saara Gladbach, Steffen Kuntoff, Nina Irmscher, Olga Hahn, Christian Junghanss, and Claudia Maletzki. 2020. “In Vivo Vaccination with Cell Line-Derived Whole Tumor Lysates: Neoantigen Quality, Not Quantity Matters.” Journal of Translational Medicine 18 (1): 1–15. doi:10.1186/s12967-020-02570-y.